Clinical trial
Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)
NCT00138099 · Hamilton Health Sciences Corporation, Other · Completed
Key facts
| NCT number | NCT00138099 |
|---|---|
| Title | Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT) |
| Official title | Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT) |
| Lead sponsor | Hamilton Health Sciences Corporation, Other |
| Collaborators | Canadian Critical Care Trials Group Pfizer Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Renal Insufficiency |
| Intervention type | Drug |
| Interventions | Fragmin (dalteparin sodium) |
| Enrollment | 140 |
| Start date | Jul 1, 2004 |
| Completion | Jun 1, 2006 |
| First posted | Aug 30, 2005 |
| Last update posted | Jun 1, 2007 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: